SMi is delighted to announce its 13th annual Clinical Trials in CNS Conference. With an ever increasing average life expectancy, neurodegenerative diseases are becoming more prevalent in society. The economic and social costs of neurodegenerative disorders to society are huge. Many big pharmaceutical companies have moved away from CNS research.
With this comes the need for new and improved therapies for treating neurodegenerative conditions. From Alzheimer's to Parkinson's disease, the target and mechanism by which a disease manifests itself presents unique challenges in how to approach such treatments not to mention ethical and legal issues behind treatment and trial design.
This conference will give delegates an opportunity to gain additional insights into the best practices in clinical trials, as well as addressing the challenges in CNS research and by looking at the latest pre-clinical and clinical studies. This is an opportunity not to be missed, as we delve into the complex and exciting world of Central Nervous System discovery, allowing delegates to learn, explore and debate the key areas of CNS, its preclinical discovery and its clinical trials.
Electronic Access - Single User Fulfilled By Publisher